Inhibitor Therapeutics Stock Market Value
| INTI Stock | USD 0.07 0.01 15.52% |
| Symbol | Inhibitor |
Inhibitor Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Inhibitor Therapeutics' otc stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Inhibitor Therapeutics.
| 11/18/2025 |
| 02/16/2026 |
If you would invest 0.00 in Inhibitor Therapeutics on November 18, 2025 and sell it all today you would earn a total of 0.00 from holding Inhibitor Therapeutics or generate 0.0% return on investment in Inhibitor Therapeutics over 90 days. Inhibitor Therapeutics is related to or competes with Devonian Health. Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patient... More
Inhibitor Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Inhibitor Therapeutics' otc stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Inhibitor Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 12.94 | |||
| Information Ratio | 0.0805 | |||
| Maximum Drawdown | 111.32 | |||
| Value At Risk | (16.25) | |||
| Potential Upside | 32.2 |
Inhibitor Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Inhibitor Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Inhibitor Therapeutics' standard deviation. In reality, there are many statistical measures that can use Inhibitor Therapeutics historical prices to predict the future Inhibitor Therapeutics' volatility.| Risk Adjusted Performance | 0.0781 | |||
| Jensen Alpha | 1.27 | |||
| Total Risk Alpha | 0.1575 | |||
| Sortino Ratio | 0.097 | |||
| Treynor Ratio | 1.69 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Inhibitor Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Inhibitor Therapeutics February 16, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0781 | |||
| Market Risk Adjusted Performance | 1.7 | |||
| Mean Deviation | 7.93 | |||
| Semi Deviation | 7.6 | |||
| Downside Deviation | 12.94 | |||
| Coefficient Of Variation | 1176.1 | |||
| Standard Deviation | 15.59 | |||
| Variance | 242.95 | |||
| Information Ratio | 0.0805 | |||
| Jensen Alpha | 1.27 | |||
| Total Risk Alpha | 0.1575 | |||
| Sortino Ratio | 0.097 | |||
| Treynor Ratio | 1.69 | |||
| Maximum Drawdown | 111.32 | |||
| Value At Risk | (16.25) | |||
| Potential Upside | 32.2 | |||
| Downside Variance | 167.55 | |||
| Semi Variance | 57.82 | |||
| Expected Short fall | (18.76) | |||
| Skewness | 2.89 | |||
| Kurtosis | 12.81 |
Inhibitor Therapeutics Backtested Returns
Inhibitor Therapeutics is out of control given 3 months investment horizon. Inhibitor Therapeutics holds Efficiency (Sharpe) Ratio of 0.11, which attests that the entity had a 0.11 % return per unit of risk over the last 3 months. We were able to interpolate and analyze data for twenty-seven different technical indicators, which can help you to evaluate if expected returns of 1.76% are justified by taking the suggested risk. Use Inhibitor Therapeutics Market Risk Adjusted Performance of 1.7, downside deviation of 12.94, and Risk Adjusted Performance of 0.0781 to evaluate company specific risk that cannot be diversified away. Inhibitor Therapeutics holds a performance score of 8 on a scale of zero to a hundred. The company retains a Market Volatility (i.e., Beta) of 0.78, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, Inhibitor Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Inhibitor Therapeutics is expected to be smaller as well. Use Inhibitor Therapeutics total risk alpha and the relationship between the potential upside and price action indicator , to analyze future returns on Inhibitor Therapeutics.
Auto-correlation | 0.06 |
Virtually no predictability
Inhibitor Therapeutics has virtually no predictability. Overlapping area represents the amount of predictability between Inhibitor Therapeutics time series from 18th of November 2025 to 2nd of January 2026 and 2nd of January 2026 to 16th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Inhibitor Therapeutics price movement. The serial correlation of 0.06 indicates that barely 6.0% of current Inhibitor Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.06 | |
| Spearman Rank Test | 0.15 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Other Information on Investing in Inhibitor OTC Stock
Inhibitor Therapeutics financial ratios help investors to determine whether Inhibitor OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Inhibitor with respect to the benefits of owning Inhibitor Therapeutics security.